Compare TG Therapeutics Inc (TGTX) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs State Street Real Estate Select Sector SPDR ETF — how do they compare? TG Therapeutics Inc trades at $47.94 (market cap $7.58B), while State Street Real Estate Select Sector SPDR ETF trades at $45.12. The key difference: State Street Real Estate Select Sector SPDR ETF is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | XLRE | |
|---|---|---|
Market Cap | $7.58B | — |
Sector | Health | Sector/Thematic |
52-Week High | $59.06 | $46.01 |
52-Week Low | $26.94 | $40.01 |
Enterprise Value | $7.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, down 0.8% with a bearish technical signal. The company reported strong revenue growth with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though earnings have missed expectations for three consecutive quarters. Analyst consensus remains bullish with 84.6% buy ratings and a $63.75 price target, representing 29% upside potential from current levels.
The outlook is mixed with strong revenue momentum from BRIUMVI offset by earnings misses and negative cash flow. Key risks include ongoing earnings underperformance, shareholder litigation, and high valuation multiples. The stock offers growth potential but requires careful monitoring of execution and profitability trends.
XLRE trades at $44.48, up 0.91% with a bearish technical signal from moving averages. The ETF shows neutral oscillators with RSI at oversold levels, suggesting potential for near-term stabilization. Recent news highlights real estate ETFs gaining attention as inflation hedges, with XLRE offering low-cost exposure to U.S. REITs at a 0.08% expense ratio. Dividend payments are scheduled for June 2026 at $0.38 per share.
The outlook for XLRE is cautiously optimistic as real estate shows resilience amid inflation pressures. Key opportunities include sector diversification and income generation, while risks center on interest rate sensitivity and economic volatility. Technical indicators suggest near-term consolidation around current price levels with support at $44 and resistance at $45.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
